Insights - Alexion Pharmaceuticals (ALXN) is buying fellow ultra orphan drug developer Synageva (GEVA) for $8.4 billion. Alexion will pay $115 in cash and 0.6581 Alexion shares … Continue Reading
Read NowInsights - The FDA just doesn’t want to meet with AcelRx Pharmaceuticals (ACRX). Reported alongside the company’s first quarter financial update, AcelRx’s request for a Type B … Continue Reading
Read NowInsights - Gilead Sciences (GILD) blew past analyst expectations in the first quarter, reporting $7.6 billion in total revenue vs. consensus estimates of $6.9 billion. More important, the company reported an impressive … Continue Reading
Read NowInsights - Shares of Pacira Pharmaceuticals (PCRX) took it on the chin at Thursday’s open as the company completely removed sales guidance for its only marketed product, Exparel. … Continue Reading
Read NowInsights - In a deal valued at $1.275 billion all-in, AstraZeneca (AZN) will partner with Innate Pharma (IPH.PA) for the development of IPH2201, Innate’s anti-NKG2A antibody. For … Continue Reading
Read NowInsights - An unexpected new contender in the race to develop a treatment for NASH (non-alcoholic steatohepatitis) emerged from a European medical conference on Thursday morning – the … Continue Reading
Read NowInsights - Teva (TEVA) made an official bid for rival drugmaker Mylan (MYL), which is in the middle of its own acquisition effort with a $29 billion bid for Perrigo (PRGO).
Read Now
